Back to today’s briefing

Story perspectives

AbbVie Acquires Capstan for $2.1 Billion Cell Therapy Breakthrough

7/1/2025

30 2

Summary

Story summary

AbbVie is set to acquire Capstan Therapeutics for a staggering $2.1 billion, unlocking groundbreaking in vivo cell therapy technology. With its promising candidate, CPTX2309, designed to combat B cell-mediated autoimmune diseases by reprogramming T cells to target CD19, this move propels AbbVie into a leading role in cell therapy research, significantly boosting its immunology expertise.

1 of 1

Story summary

AbbVie is set to acquire Capstan Therapeutics for a staggering $2.1 billion, unlocking groundbreaking in vivo cell therapy technology. With its promising candidate, CPTX2309, designed to combat B cell-mediated autoimmune diseases by reprogramming T cells to target CD19, this move propels AbbVie into a leading role in cell therapy research, significantly boosting its immunology expertise.